Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of subjecting all blood and plasma-derived products to a lower payment percentage in the Statutory Scheme Consultation, below the 10 per cent that applies to older products.

The statutory scheme consultation proposed that all older blood and plasma derived products should be subject to the lower 10% payment percentage. This is because we considered it would be appropriate to treat blood and plasma derived products differently as they are a strategically important category that has consistently been subject to global supply constraint over an extended period of time. We are considering the consultation responses and will publish our response in due course.